依达拉奉治疗急性脑出血的临床观察

目的 观察依达拉奉对急性脑出血的治疗效果.方法 将64例脑出血患者随机分为治疗组和对照组各32例.对照组按脑出血常规方法治疗,治疗组在常规治疗基础上加用依达拉奉治疗.两组于治疗前、治疗第21天分别进行中国卒中量表(CSS)与巴氏指数(BI)评分及疗效评定,并观察脑水肿程度改变及依达拉奉治疗期间的不良反应.结果 两组治疗第21天CSS和BI评分均有所改善,但治疗组明显优于对照组,CSS(10.6±5.2)分vs(13.5±5.9)分,BI(52.5±6.2)分vs(42.2±6.9)分(P＜0.05);治疗组的显效率和有效率分别为71.9%和87.5%,显著高于对照组的34.4%和62.5%(P＜0.05);治疗组第14天时中重度(2～3级)脑水肿发生率12.5%(4/32),明显低于对照组的34.4%(11/32)(P＜0.05).依达拉奉治疗期间无明显不良反应发生.结论 依达拉奉可促进脑出血患者的神经功能康复.

Clinical observation of edaravone for acute cerebral hemorrage

Objective To observe the efficacy of edaravone in treatment of acute cerebral hemorrhage.Methods Sixty-four cases were randomly divided into treatment group（n=32） and control group（n=32）.The control group was given routine treatment of acute cerebral hemorrhage.The treatment group was treated with edaravone in addition to the routine treatment received by the control group.Barthel index（BI） and Chinese Stroke Scale（CSS） and the efficacy in two groups were assessed before treatment and at 21th day after treatment.The changes of brain edema and the adverse reaction associated with the edaravone treatment were observed.Results The results of CSS and BI of two groups improved at 21th day after treatment,and CSS and BI of the treatment group were better than those of control group,CSS（10.6±5.2） points vs（13.5±5.9） points,BI（52.5±6.2） points vs（42.2±6.9） points（P0.05）;There were also significant differences between two groups in terms of apparent effect rate（treatment group 71.9%;control group 34.4%,P0.05） and improvement rate（treatment group 87.5%,control group 62.5%,P0.05）.At 14th day treatment,the incidence of 2-and 3-grade brain edema of the treatment group was 12.5%,which was lower than that of the control group（34.4%）（P0.05）.There was no distinct adverse reaction of the edaravone treatment.Conclusion Edaravone can accelerate the recovery of neural function after cerebral hemorrhage.